Latest News

EQTEC forecasts 2021 profitability

0

EQTEC (LON:EQT) said 2021 is forecast to be its first year of profitability as it targeted “considerable” sales growth from its European projects.

In a trading update on Monday, the waste gasification specialist said revenue for the financial year to December 31, 2020, is expected to be “broadly in line with market expectations” with a loss “no lower than €4mln” before any one-off adjustments.

READ: EQTEC to collaborate with Toyota on Deeside refuse derived fuel project

The company also said that following its interim results last September, the number of opportunities has grown to 75 from 41, an increase of 83%, while between July 2020 and February 2021 it has added non-contracted tender opportunities worth a total potential of €316mln for a total potential pipeline value of €657mln.

Looking ahead, EQTEC said it is aiming for considerable contracted sales growth from 6-8 projects in Europe, and that for 2021 revenues from inflight projects, new projects and gradual growth from maintenance and consulting contracts are forecast to be around €15mln with positive earnings (EBITDA), making 2021 its first profitable year.

The firm also said that the impact of the coronavirus (COVID-19), Brexit and forest fires are expected to subside throughout 2021 and there it expects “significant growth in the number, size and types of deals” over the year as well as further growth in 2022 and 2023 based on the deals in its pipeline.

“I am pleased with our progress to date – not only because amid a global pandemic crisis we grew the influence and reach of our business by further developing partnerships, pipeline and impact of EQTEC development capital, but also because of the increasing operational and managerial discipline we established”, EQTEC chief executive David Palumbo said in a statement.

“The business platform we now have in place is exactly what we set out to build and has grown our reach and impact toward building more advanced gasification plants in more markets with a greater, cleaner impact on local communities and greater returns for our shareholders. Supported by our strategic partners, we are better positioned than ever for growth and profitability in 2021 and beyond”, he added.

Medica Group makes move into the clinical trials market with RadMD acquisition

Previous article

FTSE 100 to start on back foot on one year anniversary of UK coronavirus lockdown

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News